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Abstract 
Cancer is a multifaceted process and many of its hallmarks involve complex protein-
protein interactions that dysregulate gene expression and involves yet-to-be understood activities 
of RNA helicase A (RHA), also known as DHX9.  Human T-cell leukemia virus type 1 (HTLV-
1) is a causative of adult T-cell leukemia/lymphoma (ATL), which has no cure. The viral 
oncoprotein, Tax, is necessary for cell transformation and transactivates gene transcription by 
associating with promoter DNA, various DNA binding proteins and histone acetyltransferases 
CBP/p300. Using co-immunoprecipitation assays (coIPs), we observed a physical interaction 
between CBP, RHA and RNA polymerase II. Likewise, coIPs demonstrated the physical 
interaction of RHA and HTLV-1’s post-transcriptional control element (PCE), which is 
necessary for viral RNA translation. Thus we hypothesized that RHA is necessary for the 
transcriptional, as well as post-transcriptional expression of HTLV-1. RHA (DHX9) gene 
mutations and amplifications are cataloged in the Cancer Genome Atlas and their significance 
will be discussed. To test our hypothesis, HTLV-1 LTR-Luc reporter and tax expression 
plasmids were transfected into HEK293 and HeLa cells and Luc protein and luc RNA were 
quantified by immunoblot and RT-qPCR, respectively. Exogenous expression of FLAG-RHA 
(FLAG-RHA) increased HTLV-1 LTR-Luc activity, whereas downregulation of endogenous 
RHA by siRNA reduced Luc activity to basal levels. Exogenous expression of substitution 
mutants FLAG-RHA W339A and K417R reduced luc RNA and protein activity. We postulate 
the W339A mutation abrogated the necessary physical interaction between CBP, RHA and RNA 
polymerase II.  CoIP experiments are needed to document our preliminary data indicating that 
RHA is necessary for CBP-dependent Tax-mediated HTLV-1 transcription, and its molecular 
basis is in tethering RNA polymerase II to CBP/p300 and Tax on the HTLV-1 promoter.  
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Introduction 
RNA helicase A (RHA), an essential multifunctional protein 
Cancer is a multifaceted process and many of its hallmarks involve complex protein-
protein interactions that dysregulate gene expression. One protein we believe to be involved is 
host protein, RNA helicase A (RHA) [1]. RHA, also known as DHX9, is a highly conserved 
protein, homologous to bovine nuclear DNA helicase II and Maleless protein, Mle in Drosophila 
melanogaster [1] [2]. It is absolutely essential to the cell; RHA-knockout is embryonic lethal in 
mice [3] [4]. It is known to bind both single-stranded nuclei acids and unwinds double-stranded 
nucleic acids in an ATP-dependent manner [3] [5].  A predominantly nuclear protein, RHA 
regulates expression of both viruses and cells at the transcriptional and post-transcriptional levels 
[1]. It regulates cellular transcription by interacting with RNA Polymerase II (RNA Pol II) (by its 
minimal transactivation domain MTAD of RHA, aa 331-380) and bridging to DNA binding 
proteins and tethering transcriptional factors and coactivators such as breast cancer 1 (BRCA1) , 
nuclear factor-kappa B (NF-κB), and CREB-binding protein (CBP) [1] [2] [3] [5] [6] [7] [8].  
RHA is necessary for promoting efficient translation of cellular proto-oncogenes and 
genes of the oncogenic retrovirus HTLV-1 [9] [10]. In HTLV-1, it does this by binding to an 
RNA element called the post-transcriptional control element (PCE), 160 nt stem-loop structure at 
the 5’ leader of the mRNA (5’ untranslated region). RHA performs similar functions in other 
retroviruses such as feline leukemia virus, spleen necrosis virus and human immunodeficiency 
virus (HIV) [10]. RHA has been notably associated with somatic neoplasms such as breast, 
prostate and lung [1]. Open questions revolve around the relationship between the transcriptional 
and post-transcriptional activities of RHA on oncogenes. Using HTLV-1 as a model, we 
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evaluated RHA’s specific role in HTLV-1 gene expression using reporter gene analysis and co-
immunoprecipitation. 
Human T-cell lymphotropic virus type-1 (HTLV-1), an oncogenic retrovirus 
Many viruses are responsible for infectious neoplasms in humans and animals. 
Oncogenic viruses cause approximately 12% of the known human cancers and among those is 
human T-cell lymphotrophic (leukemia) virus type 1 (HTLV-1) [11]. The existence of a human 
retrovirus was unknown to man until the late 1970’s with the discovery HTLV-1. In the 1980’s, 
HTLV-1’s more well-known cousin HTLV-III, renamed today as human immunodeficiency 
virus (HIV-1) discovered [12]. In 2012, it was estimated that over 10 million people worldwide 
are infected with HTLV-1 [13]. Endemic to southwestern Japan, Sub-Saharan Africa, South 
America and the Caribbean, the infection is associated with HTLV-1 associated 
myelopathy/tropical spastic paraparesis (HAM/TSP), and our focus, the highly aggressive adult 
T-cell leukemia/lymphoma (ATL) [14]. Approximately 3-5% of those infected progress to adult 
T-cell leukemia for which there is no treatment [15].  
HTLV-1 falls under viral family Retroviridae along with HIV-1, feline leukemia virus, 
equine infectious anemia virus, etc. Its virion structure, genetic make-up and entry receptor are 
known [15]. Thirty-six years after its discovery, the exact mechanisms of oncogenesis are still 
being discovered. It is known however that HTLV-1 encodes the oncoprotein called Tax, and 
several cellular proteins such as NF-κB and CBP, which are binding partners of RHA, have been 
identified to participate with Tax to activate gene expression [8] [7]  [16]. Thus we sought to 
elucidate the coordinate activity of Tax, CBP, and RHA. 
Tax, a viral oncoprotein critical for HTLV-1 promoter activity 
HTLV-1 encodes the viral oncoprotein Tax. Tax is crucial to viral replication and 
pathogenesis in both early and late stages. In the nucleus, Tax is absolutely required for 
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transcription from the viral promoter; it is also affects transcription of cellular genes.  In the 
cytoplasm, Tax can activate the NF-κB pathway and indirectly regulate multiple genes and 
pathways that control cellular growth such as those that control proliferation and apoptosis. 
Tax’s deregulation of these important pathways causes cellular transformation [16] [17]. A 
minority of patients progresses to ATL, but in those patients, 50% have Tax expression silenced, 
signifying that Tax is important in instigating neoplasms, but not sustaining them [18].  
As a transcriptional activator, Tax promotes efficient viral gene expression by binding 
promoter DNA and DNA-binding proteins that recruit basal transcriptional machinery. 
Specifically, Tax associates with a set of three 21 bp repeat sequences in the viral promoter 
region in the unique 3’ (U3) region of the  long terminal repeat (5’ LTR), in combination with 
phosphorylated cAMP response element binding (pCREB) protein, another cellular transcription 
factor. These sequences, called the Tax-response elements (TREs), are similar to the cellular 
cAMP-response elements (CREs) to which CREB binds [14] [19]. Tax does not physically bind 
to TREs, which are bound by CREB, but associates with GC-rich sequences flanking the TREs.  
Tax mediated activation of cellular CRE-containing promoters is dependent on the 
presence of phosphorylated CREB (pCREB) [19] [20]. Protein kinase A (PKA) is the cAMP-
activated kinase that is largely responsible for phosphorylating CREB at Ser-133 [21]. A 
phosphorylated CREB then functions coordinately with Tax to recruit other transcriptional 
coactivators such as CBP/p300.  
CBP/p300, players in transcription and cellular transformation 
Cellular proteins tying together the two ends of our story are DNA coactivators: CREB-
binding protein (CBP) and paralog E1A-binding protein (p300). Though each protein does have 
its own distinct role in certain biological settings, CBP and p300 are generally held to be 
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functionally redundant [22]. CBP/p300 is a transcriptional coactivator that functions with basal 
transcription factors and other DNA binding proteins to activate transcription of a multitude of 
genes. Specifically CPB/p300 has histone acetyltransferase (HAT) activity that regulates 
chromatin. In cells chromatin is organized into nucleosomes, complexes of histone proteins with 
DNA tightly wrapped around them, so that most of the DNA is inaccessible to basal 
transcriptional factors and other transcriptional machinery.  CBP/p300’s HAT activity modifies 
histones via acetylation, which causes the nucleosome to be more accessible to transcriptional 
machinery. Their HAT domains are also capable of modifying other transcription factors to 
regulate their activity [22] [23].  
CBP/p300 frequently interacts with important transcriptional coactivators of RNA Pol II-
dependent transcription, including basal transcription factors such as TATA-binding protein that 
are necessary to initiate transcription [22]. RHA is an important mediator that functions by 
bridging RNA Pol II and CBP/P300 transcriptional coactivation complex. Specifically, the N-
terminal domain of RHA (aa 1-250) binds to the C/H3 region (aa 1805-1890) of CBP [8]. Both 
cellular and viral genes are transcriptionally responsive to CBP/p300 tethered by Tax to other 
DNA-binding proteins at the viral TREs. CBP’s KID interaction (KIX) domain (aa 588 - 683) 
simultaneously binds to phosphorylated CREB’s kinase interaction domain (KID; aa 100-160) 
and Tax’s KID-like domain (aa 81-95). CBP also interacts with Tax at a second domain, the C-
terminal transcriptional activating domain (CR2; aa 312-319), indicating that Tax/CBP 
interaction is important at the viral promoter [24].  
CBP/p300 has an integral role in cancer. Chromosomal translocation involving 
CBP/p300 genes have been connected with leukemia/lymphoma. CBP/p300 not only functions 
with tumor-suppressor proteins such as p53, but also with oncogenic transcriptional co-activators 
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such as c-jun. Both CBP and p300 are targets for DNA viruses that cause cellular transformation, 
such as Epstein-Barr virus (EBV)  [23]  [25]. 
 Considering all these observations, we have investigated the molecular basis for the 
coordinate interaction of RHA, Tax and CBP/p300 in the regulation of viral gene expression, 
which ultimately leads to cellular transformation. Our experimental hypothesis is that RHA is 
necessary for Tax–mediated, CBP-dependent viral gene transcription (Fig. 1).  
Significance of this study  
Protein-protein and DNA-protein interactions significantly contribute to mechanisms of 
disease and viruses utilize these interactions in their replication. Studying the cooperative effects 
of RHA, CBP/p300 and Tax on gene transcription is a necessary step to uncover RHA/viral 
protein and host protein/viral protein interactions in HTLV-1 and other viruses and to expose 
their instruments of infection. 
 In cancer, the web of such interactions is typically altered from normal cell biology in a 
myriad of ways. Looking at somatic mutations in disease and altered interactions provides a key 
to understanding at the molecular level and knowledge on how cell biology can be changed or 
reverted back to its original state. Understanding the interface between RHA, CBP/p300 and Tax 
is important to dissecting ATL caused by HTLV-1 and to other cancers in somatic neoplasms. 
RHA’s gene alterations in different cancers through bioinformatics from the Cancer Genome 
Atlas (TCGA) are identified and provide insight on specific copy number changes or mutations 
of the gene [26] [27]. These alterations may well be the same ones used by oncogenic viruses for 
their own use and to facilitate cellular transformation. 
 To this day there is a dearth of knowledge on how ATL arises in patients infected with 
HTLV-1 and in long term, this information is necessary to therapeutically halt the virus and 
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eventually the cancer. The knowledge obtained from this study can be tied back to cancer studies 
in general. The viral model of RHA, CBP/p300 and Tax interactions may exist in cancerous cells 
in the form of other CBP/p300 complexes, functioning with other DNA binding adaptor proteins 
like Tax, that require RHA for the transcription of specific genes. Such cellular transcription 
models are especially important in the context of cancer and gene regulation during cellular 
transformation. In conclusion, this study has a lot to contribute to two very important fields of 
retrovirology and oncology. 
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Methods 
Plasmids 
The previously described plasmids used in this study are empty-FLAG plasmid (pCDNA) 
and FLAG-RHA plasmid [28]. K417R and W339A plasmids were made based on previous 
literature [3] [8]. pRenilla was obtained from Promega. 
CMV-Tax expression plasmid, CMV-HBZ expression plasmid & HTLV-1 LTR-luc 
reporter gene plasmid were obtained from Dr. Patrick Green (The Ohio State University). GFP-
Tax and wild-type PKA (WT-PKA) plasmids were obtained from Dr. Susan Marriott (Baylor 
College of Medicine). 
 
Cells and transfections 
HEK293 cells were grown in EMEM (ATCC) with 10% fetal bovine serum and 1% 
antibiotic/antimycotic. For the overexpression studies, HEK293 cells (5 × 10
5
 cells/plate in 6-
well plates) were transfected with pCDNA (1 µg), wild-type FLAG-RHA (1 µg) and RHA 
mutant (2 µg each) after 24 hrs, followed by Tax (0.2 µg) plasmid transfection and HTLV-1 
LTR-Luc (0.1 µg) plasmid cotransfection after 48 hrs with X-tremeGENE HP (Roche) at a 1:3 
DNA to X-tremeGENE ratio, according to the manufacturer’s protocol.  
HeLa cells were grown in EMEM (ATCC) with 10% fetal bovine serum and 1% 
antibiotic/antimyotic. For the downregulation studies, HeLa cells (2 × 10
5
 cells/plate in 6-well 
plates) were reverse transfected with siRNA complementary to the RHA mRNA or nonsilencing 
control siRNA consisting of a scrambled (Sc) sequence at a final concentration of 10 nM in 
Lipofectamine 2000 (Invitrogen), Opti-MEM media (Invitrogen) and EMEM (ATCC) with 10% 
fetal bovine serum, according to a published protocol [29]. Cells were rinsed twice and freshly 
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incubated in EMEM (ATCC) with 10% fetal bovine serum and 1% antibiotic/antimyotic for 24 
hrs. Cells were then cotransfected with CMV-Tax (0.4 µg) and CMV-HBZ (0.4 µg). At 48 hrs, 
cells were cotransfected with HTLV-1 LTR-Luciferase (0.1 µg) and pRenilla (0.025µg). All 
transfections were carried out with X-tremeGENE HP (Roche) at a 1:3 DNA to X-tremeGENE 
ratio, according to the manufacturer’s protocol.  
 
Luciferase assay and RNA analysis  
HEK293 and HeLa cells were scraped, centrifuged and lysed with 1X Passive Lysis 
Buffer (Promega) following the manufacturer’s protocol. Cellular lysates were then treated with 
Luciferase Assay Reagent (Promega) following the manufacturer’s protocol and 
photoluminescence measured by a standard luminometer. For cells transfected with pRenilla, 
additional reagents were added and the Dual Luciferase (Promega) protocol was followed.  
Total cellular lysates obtained for the Luciferase assays were also used for RNA 
extractions. Total RNA was isolated with Trizol LS reagent (Invitrogen) and purified with 
RNAeasy MinElute Cleanup Kit (Qiagen) following the manufacturer’s protocol. RNA 
concentration was determined by spectrophotometer (NanoDrop). Isolated RNA was treated with 
Turbo DNA-free Kit (Life Technologies) and used to prepare cDNA in a 20 uL-reaction mixture 
with Omniscript reverse transcriptase (Qiagen) following the manufacturer’s protocol. 
Quantitative PCR was performed with 2 uL of cDNA with CFX96 Real Time System (BioRad). 
Primers KB1747 Luc and KB1748 Luc were used to amplify the PCR product. RNA samples 
without reverse transcriptase were used as negative controls. Details on primer sequences are 
available on request. 
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Immunoprecipitation and immunoblot analysis 
HEK293 and HeLa cells were grown in EMEM (ATCC) with 10% fetal bovine serum 
and 1% antibiotic/antimyotic. HEK293 cells (1.5 × 10
6
 cells/plate in 10 cm plates) were serially 
transfected with FLAG-RHA (2 µg) and GFP-Tax (2µg) 24 hrs and 48 hrs after plating, 
respectively. Cells were scraped, washed and lysed in RIPA buffer (50 mM Tris pH 8.0, 0.1% 
SDS, 1% Triton-X, 150 mM NaCl, 1% deoxycholic acid, 1% protease inhibitor cocktail, 0.1% 
DTT). Sepharose pre-conjugated FLAG beads (Sigma Aldrich) were blocked with 0.5% BSA 
and washed with NETN-150 buffer (0.5% NP40, 0.1 mM EDTA, 20 mM Tris-HCl pH 7.4, 150 
mM NaCl). Lysates were added to the beads and incubated for 3 hrs at 4°C.  Following the 
incubation, complexes were washed thrice with NETN-150 buffer and twice with wash buffer 
(50 mM Tris-HCl pH 7.4, 150 mM NaCl). IP efficiency was assessed by immunoblotting 
equivalent aliquots of input and flow-through lysates. A control IgG rabbit IP was performed 
alongside. 
HeLa cells (1 × 10
6
 cells/plate in 10 cm plates) were transfected with WT-PKA (2.5 µg), 
scraped, washed and lysed in RIPA buffer. The lysates with and without PKA (control) were 
added to IgG mouse and IgG rabbit (Sigma Aldrich) conjugated Protein G magnetic beads 
(Invitrogen) for 30 min at 4°C in order to pre-clear the lysates. Pre-cleared lysates were then 
added to RHA (Vaxron) conjugated Protein G magnetic beads (Invitrogen) and incubated for 2 
hrs at 4°C. Following the incubation, complexes were washed thrice with NETN-150 buffer. IP 
efficiency was assessed by immunoblotting equivalent aliquots of input and flow-through 
lysates. 
SDS-PAGE was performed by loading equal amounts of protein (5 or 10 µg) or equal 
loading volumes of 40 uL (only for the co-IP assays) on  4-15% Mini-Protean TGX
TM
 gradient 
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gels (Bio-Rad). Proteins were transferred onto nitrocellulose membranes and probed with 
appropriate antibodies. The antibodies used for immunoblotting were: FLAG (1:5000, Sigma-
Aldrich F7425), α-tubulin (1:1000, Santa Cruz sc-23948), RHA (1:7500, Vaxron PA-001), CBP 
(1:500, Santa Cruz sc-7300) and Pol II (1:200, Santa Cruz sc-9001). 
 
Statistical analyses 
The Luciferase assays were conducted in triplicate with three independent samples for 
each condition. RT-qPCR was also conducted in technical triplicate with three reactions from 
one sample of each condition. CoIPs were conducted with individual samples without replicates. 
Two-tailed student t- tests were used to test significance comparing p-values with α = 0.05. 
Bioinformatics of the Cancer Genome Atlas (TCGA) 
The results discussed below are in whole or part based upon data generated by  the 
Cancer Genome Atlas (TCGA) Research Network: http://cancergenome.nih.gov/. cBioPortal for 
Cancer Genomics was primarily used for simplifying data analyses of the data provided by 
TCGA and generating the results below. TCGA contains both published and unpublished data 
sets (indicated as provisional data). The cBioPortal site only stores detailed mutation data for 
published cancer studies as the National Cancer Institute guidelines prevent provisional data 
from being redistributed until they have been validated [26] [27].  
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Results 
RHA downregulation negatively affects Tax-dependent HTLV-1 gene expression 
To examine the effect of RHA downregulation on Tax-mediated CBP-dependent activity 
of the HTLV-1 promoter, luciferase assays were conducted with HTLV-1 LTR-Luc reporter 
plasmid, Renilla expression plasmid for transfection efficiency control, and Tax expression 
plasmid with and without siRNA mediated down regulation of RHA. The HTLV-1 LTR-Luc 
reporter plasmid contains the 3’ LTR viral promoter upstream of the Luciferase gene (Fig. 3). 
siRNAs were transfected initially followed by Tax transfection and lastly HTLV-1 LTR-Luc 
plasmid transfection into HeLa cells. Successful knockdown (KD) was confirmed by WB 
analysis (Fig. 4). Firefly luciferase (Luc) activity was measured and normalized to Renilla 
luciferase expression. In the absence of Tax, siRNA-mediated RHA KD did not have any effect 
on Luc activity. In the presence of Tax, however, siRNA-mediated RHA KD resulted in a 
decrease of Luc activity by a factor of 20 compared to Luc activity of cells without RHA KD. 
Noticeably, these levels were approximately equal to Luc with RHA KD but without Tax 
expression, indicating that both RHA and Tax are required at threshold levels for HTLV-1 gene 
expression (Fig. 4).  
RHA overexpression positively affects Tax-dependent transactivation of the HTLV-
1 promoter 
After observing that minimal levels of RHA are required for HTLV-1 promoter activity, 
we decided to examine the effect of RHA overexpression on Tax-mediated CBP-dependent 
activity of the HTLV-1 promoter. Luciferase assays were conducted with HTLV-1 LTR-Luc 
reporter plasmid, Tax, pCDNA, FLAG-RHA, K417R and W339A expression plasmids. pCDNA 
is an empty-FLAG control plasmid. K417R is a mutant RHA plasmid containing a Lys to Arg 
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point mutation at aa 417 in the ATP-binding domain of RHA that is necessary for RHA’s 
helicase activity and important both for transcription and translation [8] [28].  W339A is a 
mutant RHA plasmid containing a Trp to Ala point mutation at aa 339 in the minimal 
transactivation domain (MTAD) of RHA that interacts with RNA Polymerase II (RNA Pol II) 
and is necessary for CREB-dependent transcriptional activation [3]. We expected luciferase 
activity to decrease under the mutant transfection conditions. The RHA expression plasmids 
were transfected 24 hrs after the cells were plated, followed by co-transfection of Tax and 
HTLV-1 LTR-Luc plasmids at 48 hrs. Transfection of the RHA expression plasmids was 
confirmed by Western blot (WB) analysis. Firefly luc activity was measured and statistically 
analyzed. 
 In the presence of Tax, cells overexpressing wild-type RHA (FLAG-RHA) presented a 
5-fold increase of Luc activity compared to the pCDNA control. Cells transfected with RHA 
mutants K417R and W339 presented a decrease in Luc activity by a factor of 8 and a factor of 
15, respectively relative to the Luc activity of FLAG-RHA overexpressing cells (Fig. 5). Without 
Tax, luciferase expression is too low even with wild-type RHA overexpression (figure not 
shown).  These observations show that Tax-dependent transcriptional activation of the HTLV-1 
promoter increases in response to RHA overexpression, but decreases when RHA mutants are 
overexpressed. The results indicate that K417R and W339A mutants have a dominant negative 
effect and that the MTAD and ATP-binding domains of RHA are essential for RHA and Tax’s 
collective functionality in regulating HTLV-1 gene expression.  
To discern between a transcriptional and post-transcriptional level of interaction, we 
conducted quantitative real-time reverse transcriptase polymerase chain reactions (RT-qPCR). 
Total RNA was extracted, DNAse treated and converted to cDNA, followed by primer-specific 
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amplification of luciferase messenger RNA (luc mRNA). The mRNA was quantified based on a 
standard curve and normalized by volume. The results showed significant decreases of luc 
mRNA in response to mutant K417R and W339A compared to the control pCDNA condition by 
a factor of 1.5 and a factor of 4, respectively (Fig. 6). The luc mRNA levels showed significant 
decreases in response to mutant K417R and W339A compared to the FLAG-RHA condition by a 
factor of 7 and a factor of 19, respectively. The luc mRNA levels showed a 4-fold increase when 
FLAG-RHA was overexpressed compared to the luc mRNA levels of the pCDNA control. 
 Further analysis through the comparison of Luciferase activity/luc RNA ratios 
demonstrated no significant difference between basal RHA expression (pCDNA), and wild-type 
overexpression (FLAG-RHA) and overexpression of K417R mutant (Table 1). This shows that 
FLAG-RHA solely altered the transcriptional efficiency of luc RNA but not the translational 
efficiency. The K417R mutant, being important for both transcription and translation decreased 
both luc RNA levels and protein significantly compared to pCDNA condition so it is expected 
that this condition’s Luc activity/luc RNA ratio was not significantly different from the pCDNA 
condition. Unexpectedly, the W339A mutant expression, despite decreasing both luc RNA levels 
and protein significantly compared to pCDNA condition, significantly increased the Luc activity 
per RNA copy implying RHA’s role in increasing translational efficiency. The increase in 
translation efficiency was able to compensate for decrease transcriptional efficiency to produce 
more Luc activity per copy of luc RNA. This result in particular suggests a dual role of RHA at 
both transcriptional and translational levels (Fig. 1).  
Further experiments need to be conducted with the mutants to discern exactly how much 
of a role RHA plays at both transcriptional and post-transcriptional stages and in what settings. 
Despite the lack of significant differences between the Luc activity/luc RNA ratios when 
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comparing the control (pCDNA) to FLAG-RHA and K417R mutant conditions, the significant 
increases and decreases in Luc protein and luc RNA alone suggest that either transcriptional or 
translational efficiency is being increased (Table 1). For example, K417R mutant might cause a 
decrease in transcriptional efficiency as shown by the significant decrease in the mRNA number 
compared to the control, but perhaps it is still able to function to enhance translational efficiency 
or the endogenous RHA could be sequestered to the cytoplasm to function post-transcriptionally, 
which is why we haven’t observed a significant decrease in the Luc activity/luc RNA ratio 
compared to the control. Experiments tailored to discern RHA’s function only at the 
transcriptional or post-transcriptional level in this context can illuminate the protein’s specific 
roles. 
RHA and Tax are capable of binding to each other in a biological setting 
Based on the coordinate functional activity between RHA and Tax as suggested by the 
downregulation and overexpression studies, we decided to test whether RHA and Tax’ functional 
role had a physical, molecular basis. Co-immunoprecipitation (CoIP) assays were performed to 
see if the proteins were part of the same transcriptional complex. After plating, HEK293 cells 
were transfected with FLAG-RHA (2 µg) at 24 hrs and GFP-Tax (2µg) at 48 hrs. Soluble total 
cell lysates were immunoprecipitated with pre-conjugated anti-FLAG beads. Western blot 
analysis of the protein complexes in the FLAG immunoprecipitant was performed using an anti-
GFP antibody and it confirmed that GFP-Tax was co-immunoprecipitated (Fig. 7). A positive 
control, CBP80 and a negative control, eIF4E were also analysed via WB to validate a successful 
CoIP. Our lab has shown that CBP80 does bind to RHA whereas eIF4E does not (unpublished 
data, Boris-Lawrie, K.). Both low and high exposures were conducted. WB analysis suggested 
that Tax has an affinity for RHA and they are capable of binding to each other in vivo.  
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To validate the previously published interactions of RHA with CBP and RNA Pol II, 
endogenous CoIP assays were performed with HeLa cells. HeLa cells were transfected with WT-
PKA (2.5 µg) 24 hrs after plating. Cells were scraped and lysed. Lysates were added to magnetic 
beads conjugated with IgG mouse antibody for pre-clearing. Pre-cleared lysates were 
immunoprecipitated with RHA antibody-conjugated magnetic beads. Immunoblot analysis of the 
protein complexes in the RHA immunoprecipitate confirmed that CBP and RNA Pol II were co-
immunoprecipitated (Fig. 8).  
Genotypes of RHA (DHX9) in tumors, bioinformatics of patient neoplasms 
The Cancer Genome Atlas (TCGA) is a large project that aims to catalogue all the 
mutations involved in different cancers through the use of sequencing and bioinformatics. 
cBioPortal for Cancer Genomics is an online resource that provides user-friendly ways to 
analyze and manipulate the genomic data (published and unpublished) provided by TCGA [26] 
[27]. One of these ways is to access the data sets based on a single gene, in our case, RHA (listed 
as DHX9 in the database).  Ways to view the data sets include alteration frequency bar graphs, 
mutation plots over the protein domains, and multi-categorical tables. 
To examine how frequently RHA was altered in various cancers, alteration frequency bar 
graphs were generated looking at how frequently the gene was “totally altered” (including all 
changes and mutations), amplified and mutated. Five specific studies (selected based on having 
the highest “total alteration” frequencies) and two studies on acute myeloid leukemia (AML) 
were selected (Fig. 9A). Those five studies were also highlighted on frequency bar graphs 
representing copy number alterations (CNA) and mutations exclusively (Fig. 9B,C). This 
information is also organized in table format (Table 2). Two breast cancer studies (breast cancer 
patients xenografts and breast invasive carcinoma), one liver cancer study (hepatocellular 
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carcinoma), one pancreatic cancer study (pancreatic adenocarcinoma) and one uterine cancer 
study (uterine carcinosarcoma) were among the selected studies for having the highest total 
alteration frequencies of RHA.  
A horizontal plot with all of RHA’s mutations and their frequency of occurrence among 
all catalogued cancer studies was generated (Fig. 9D). Specifically, mutations of three select 
regions are highlighted on the plot. These regions of interest include RHA’s N-terminal domain 
(aa 1-250) that interacts with CBP, minimal transactivation domain (MTAD at aa 331-380)  that 
interacts with RNA Polymerase II and a region overlapping the double-stranded RNA-binding 
domain 2 (dsRBD2, aa 230-325) that interacts with BRCA1 (Fig. 9E). Mutations in these three 
regions that were observed in the any of the selected seven cancer studies and their predicted 
functional impact score are shown in a table (Table 3). Specifically, four missense mutations 
D206G, I23V, V40G, and L117R were found in studies for liver, hepatocellular carcinoma, 
breast invasive carcinoma, pancreatic adenocarcinoma and uterine carcinosarcoma, respectively. 
All of these mutations are found in RHA’s N-terminal domain in a region that bridges CBP to 
RNA Polymerase II. Further studies on the mutations’ functional impact will reveal the necessity 
of RHA/CBP interaction for proper gene expression regulation, which, when disrupted, can lead 
to cellular transformation.  
An alteration frequency bar graph highlights five studies among all cancer studies based 
on highest amplification or deletion type alteration frequencies (Fig. 10). These studies include 
one breast cancer study (breast invasive carcinoma), one liver study (hepatocellular carcinoma), 
one lung study (lung adenocarcinoma), one uterine cancer study (uterine carcinosarcoma) and 
one ovarian cancer study (ovarian serous cystadenocarcinoma). An alteration frequency bar 
graph also highlights five studies among all cancer studies based on highest mutation type 
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alteration frequencies (Fig. 11). These studies include two bladder cancer studies (bladder 
urothelial carcinoma, published and unpublished), one pancreatic cancer study (pancreatic 
adenocarcinoma), one colorectal cancer study (colorectal adenocarcinoma) and one lung cancer 
study (small cell lung cancer). These results indicate the prevalence of RHA gene alterations in a 
wide range of cancers.   
Lastly, all “validated” mutations of DHX9 are shown in a multi-categorical table 
generated by cBioPortal (Fig. 12). Most of these mutations pertain to colorectal cancer. In 
particular, three colorectal cancer studies show valid missense mutations in our regions of 
interest. Ovarian and lung cancer studies also show valid mutations. In particular, the lung cancer 
study shows a missense mutation in RHA’s MTAD region. This table is useful way to explore a 
particular sample and/or cancer study. It also allows users to view the information through 
different categories by viewing all mutations in numerical order based on amino acid, assessing 
highest functional impact mutations, examining the validation status and more.  
Role of RHA’s amplification at transcriptional and post-transcriptional levels 
The overexpression of wild-type RHA (FLAG-RHA) resulted in significant increases of 
luc mRNA transcription and Luc protein activity. In the context of the bioinformatics results 
described above, it can be implied that similar effects are being observed on RHA-mediated gene 
expression in those cancer studies that show copy number amplification of RHA (DHX9). 
Through gene amplification, increased RHA expression can subsequently upregulate 
transcription and translation of proto-oncogenes in cancerous cells.  These implications open up 
new possibilities for future experimental directions as well as the mechanisms underlying 
cellular transformation. 
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Discussion 
RHA as a transcriptional regulator 
RNA helicase A (RHA) is a multifunctional host protein that has been shown to regulate 
gene expression at both transcriptional and translational levels. Its cellular transcriptional 
interactions with p300/CBP histone acetyltransferase proteins and RNA Polymerase II 
implicated a potential coordinate role with Tax, a viral oncoprotein that interacts with p300/CBP 
and other DNA binding elements in the viral context of HTLV-1 infection. Here, we demonstrate 
the functionality of that partnership by showing the effects of RHA overexpression and 
downregulation with and without Tax. Indeed, the overexpression of RHA protein in conjunction 
with basal levels of Tax upregulates the expression of a reporter gene that contains the HTLV-1 
viral promoter. On the contrary, siRNA-mediated downregulation of RHA despite having basal 
levels of Tax significantly lowers the expression of the same reporter gene.  The functional 
coordination between the two proteins is necessary to have an effect on gene transcription as 
shown by the insignificant changes in reporter gene transfection under RHA overexpression or 
downregulation when Tax is absent, indicating that Tax is a necessary player. 
The decreased reporter gene expression during the overexpression of RHA mutants 
K417R and W339A is an important indication of two things: the mutants are functioning as 
previously reported (dominant negative in the cellular context) and that not only do they have a 
similar role in the specific viral context of HTLV-1 infection but also that RHA is actively 
regulating gene expression at a transcriptional level.   
Quantitative analysis of the reporter gene mRNA revealed further insight of the nature of 
the functional interaction between RHA and Tax. Decreased mRNA levels of the reporter gene 
during the overexpression of the RHA mutants affirm previous literature regarding the 
transcriptional importance of the specific amino acids belonging to the select domains of RHA, 
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in addition to indicating similar transcriptional roles and importance of said amino acids in the 
context of viral gene expression. 
RHA as a post-transcriptional regulator 
Further analysis through the comparison of Luciferase activity/luc RNA ratios presented 
expected and unexpected results. There was no significant increase in the ratio when comparing 
FLAG-RHA and K417R mutant condition to the pCDNA control but there was a significant 
increase in the ratio for the W339A mutant condition. Wild-type RHA (FLAG-RHA) functioned 
to increase transcriptional efficiency of Luc reporter gene with normal translational efficiency as 
indicated by the increase in both Luc activity and luc mRNA. The K417R mutant condition 
maintained a statistically similar Luc activity/luc RNA ratio by decreasing efficiency of 
transcription and maintaining normal translational activity as indicated by the decrease in both 
Luc activity and luc mRNA. 
 The W339A mutant condition unexpectedly resulted in a significant increase in Luc 
activity/luc RNA ratio. Though both Luc activity and luc mRNA levels significantly decreased in 
the W339A condition, the fact that the Luc activity/luc RNA ratio increased indicates increased 
translational efficiency. Since this mutant significantly affects RHA’s transcriptional activity by 
preventing its proper interaction with RNA Pol II, it is possible that RHA is being recruited to a 
post-transcriptional complex to increase translational efficiency in order to compensate for the 
decreased transcriptional efficiency. This not only implies that RHA plays a dual role in viral 
gene expression but also that context plays an important role in directing RHA’s degree of 
involvement at the transcriptional and post-transcriptional levels.     
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RHA tethers Tax to RNA Pol II 
The interaction between RHA, CBP and RNA Pol II and potential link between RHA and 
Tax, further supports our hypothesis of RHA being a key host-factor in CBP/p300-dependent 
gene regulation of the viral genome. While a lack of proper antibody for Tax makes it difficult to 
assess endogenous/untagged Tax and RHA interaction, successful pull-down of GFP-Tax with 
RHA IP is indicative of the affinity between these two proteins. On the other hand, seeing that 
CBP and RNA Pol II were not pulled down when GFP-Tax was transfected into cells (figure not 
shown) indicates a possible post-transcriptional interaction between RHA and Tax, away from 
transcription factors such as CBP and RNA Pol II. Combining the new data regarding RHA and 
Tax’s potential interaction and RHA’s already established transcriptional bridging role, it is 
likely that RHA functions to tether Tax to RNA Pol II for efficient transcription of the viral 
genome.  
In conclusion, much of data supports our hypothesis that RHA is necessary for CBP-
dependent viral gene regulation at the transcriptional level, most likely by linking Tax to RNA 
Pol II, in addition to supporting a dual role played by RHA in conjunction with Tax at the post-
transcriptional level.  
RHA alterations are prevalent in selected cancers 
Literature supports RHA’s importance in cancers such as breast, prostate and lung, but 
using a bioinformatics approach to survey RHA’s prevalence in other cancers has shown that it is 
altered in many different cancers. cBioportal analysis of TCGA reveal that RHA is altered in a 
total of 55 different types of cancer studies.  Some studies show only RHA copy number 
variation such as the BCCRC Breast Xenograft studies, some studies only show RHA mutations 
such as Genentech’s Colorectal Cancer studies and a majority of studies show that RHA is both 
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altered in number (copy number variation; CNA) and gene structure (mutations). The occurrence 
of RHA alterations in such a wide variety of cancers suggests many possibilities. RHA might 
have a common function or might be a part of a common pathway that is altered or deregulated 
during cellular transformation. Since so many studies show RHA amplification, there is also the 
possibility that normal RHA is just playing an abnormal role in the cell.  
As TCGA contained no data on ATL, we hoped to examine data on another blood-borne 
cancer: Acute Myeloid Leukemia. Data analysis showed that only 0.5% of samples in two groups 
of AML studies showed RHA CNA and no data were found to indicate any RHA mutations in 
AML. These results are inconclusive without further studies about RHA’s involvement in ATL. 
We explored and analyzed RHA’s mutation data based on the possibility that RHA’s 
normal function or role in cellular pathways being altered leads to cellular transformation. Based 
on our hypothesis, that RHA is necessary for Tax–mediated, CBP-dependent viral gene 
transcription and that these interactions might be of importance in cellular transformation, 
mutants in relevant domains of RHA were explored. Four missense mutations D206G, I23V, 
V40G, and L117R were found in RHA’s N-terminal domain in a region that bridges CBP to 
RNA Polymerase II. There is a possibility that each of these mutations, by disrupting the 
RHA/CBP interface and therefore preventing RNA Pol II to associate with CBP, are contributing 
to dysregulation of gene expression that might contribute to cellular transformation in the long-
term. 
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Future Directions 
The results of this study support our hypothesis that RHA is necessary for Tax-
mediated, CBP-dependent viral gene transcription. While further studies can be conducted in 
any of the areas in this study, two possible future directions involve further examining RHA’s 
role in the context of HTLV-1 biology and/or the context of cancer biology.  
To elucidate RHA’s exact mechanisms and role in HTLV-1 infection and transformation, 
the virus-host interface can be studied endogenously; experiments similar to ones conducted in 
this study can be performed in HTLV-1 infected T-cells (SLB-1 cell line). Protein-protein 
interactions involving RHA, Tax, CBP/p300 and other relevant proteins can also be studied 
using patient tissue samples to place molecular discoveries in the direct context of HTLV-1 
disease.  
 The second area of exploration involves discovering and understanding RHA’s role in 
cancer biology. Further bioinformatics exploration might reveal significant mutations of RHA 
which can then be cross-checked against mutations of RHA-binding proteins such as CBP/p300 
in other cancers. That information can be used to understand RHA and its binding partners’ role 
in instigating or sustaining neoplasms, for example through cell transformation assays using 
mutant forms of the proteins.  
Lastly, long-term studies can be directed towards hindering RHA’s interaction with 
certain proteins in certain pathways that contribute to cellular transformation or tumor sustenance 
or supporting an opposite role of RHA through drug development. Several drugs in the market 
already target CBP/p300 at specific sites and new drugs that target RHA’s specific domains to 
hinder or promote its activity can be developed [23]. 
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Figure 1.   Our current working model of RHA in HTLV-1 transcription and translations 
Figure 3. HTLV-1 LTR-Luc reporter plasmid with the 5’ LTR viral promoter and Luciferase gene. 
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Figure 2. RHA’s domain structure and mutation locations.  Adapted from [2]). 
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Figure 4. 
siRNA-mediated downregulation of RHA significantly decreases Luciferase protein activity in the presence of Tax. 
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 A        B      C       D 
A - pCDNA + Luc + CMV-Tax 
B - FLAG-RHA + Luc + CMV-Tax 
C - K417R + Luc + CMV-Tax 
D - W339A + Luc + CMV-Tax 
RHA 
α-Tubulin 
Figure 5. 
(Left) Firefly luciferase activity statistically analyzed. Effects of wild-type RHA and RHA mutants K417R and 
W339A overexpression on Tax driven luciferase reporter plasmid expression in HEK293 cells. pCDNA (1 µg), 
wild-type RHA (1 µg) and RHA mutant (2 µg each) transfections were carried out first, followed by Tax (0.2 
µg) plasmid transfection and HTLV-1 LTR-Luc (0.1 µg) plasmid cotransfection. The values obtained are 
averages of triplicates from 1 experiment. Error bars indicate standard deviation. (Right) The western blot 
analysis of exogenous RHA protein levels in cytoplasmic lysates of cells assuring equal exogenous RHA-protein 
expression. 
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Figure 6. 
 (A) RNA analysis by RT-qPCR showed 
that steady state Luciferase mRNA 
levels were approximately the same 
with and without wild-type expression. 
RNA levels also decreased significantly 
when the mutants were overexpressed. 
(B) Standard curve for RT-PCR. (C) 
Threshold cycle (Ct) values of 
experimental samples normalized to 
samples with no reverse transcriptase 
(NRT).  
FLAG-RHA 
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 Figure 6 cont’d. 
 (D&E) Melting curves of PCR product to validate PCR accuracy and a lack of non-specific reaction products.  
D 
E 
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Figure 7. 
RHA and Tax, as two proteins, have some affinity for and are capable of binding to each other in a biological 
setting. In our hands two controls that have been shown to bind or not bind to RHA – CBP80 (positive) and 
eIF4E (negative) – are used to validate a successful IP. 
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Figure 8. 
Endogenous RHA forms a complex with endogenous CBP and endogenous RNA Polymerase II as 
supported by previous literature.  
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Figure 9. 
(A) Five specific studies were selected based on having the highest “total alteration” frequencies. 
(B)The same five studies among all cancer studies based on highest amplification or deletion type alteration 
frequencies. 
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Figure 9 cont’d. 
(C) The same five studies among all cancer studies based on highest mutation type alteration frequencies. 
(D)A plot of all known RHA mutations among cancer studies across the protein structure with a figure 
legend provided by the site. (E)Shaded boxes represent specific domains of RHA relevant to our study. 
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A region overlapping the double-stranded RNA-binding domain 2 
(dsRBD2, aa 230-325) interacts with BRCA1 
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Figure 10. 
Five studies among all cancer studies based on highest amplification or deletion type alteration frequencies. 
(Highlighted in red are cancers from among our previously selected five.) 
 
Figure 11. 
Five studies among all cancer studies based on highest mutation type alteration frequencies. (Highlighted in 
green is a cancer from among our previously selected five.) 
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Figure 12. 
cBioPortal’s gene data can be organized into multiple categories. The current view is organized based on all 
“valid” mutations, in alphabetical and numerical orders depending on the cancer type first and then the 
sample ID. 
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Table 1. 
The effects of RHA overexpression on luciferase RNA and protein expression.  
Table 2.  
Summary of data samples with RHA (DHX9) copy number alterations (CNA) and/or mutations among the selected five cancers and 
AML. This data is based off  Figures 9A, 9B & 9C. * Tumor sequencing data is indicative of samples containing mutations.  
 
Note: The cBioPortal site only stores mutation data for published cancer studies. Mutation data for provisional cancer data sets 
generate by The Cancer Genome Atlas (TCGA) are not stored. Provisional data is indicated above as TCGA unpublished; otherwise all 
data is published. National Cancer Institute guidelines prevent provisional data from being redistributed until they have been validated. 
HTLV-1 LTR-
Luc
RNA (copy 
number/uL)
Significance 
(compared to 
pCDNA)
Protein (relative 
light units/uL)
Significance 
(compared to 
pCDNA)
Protein/RNA
Significance 
(compared to 
pCDNA)
pCDNA 676 ± 59 N/A 7188 ± 315 N/A 11 ± 1 N/A
FLAG-RHA 2961 ± 268
Significant         
(p ≤ 0.05) 38976 ± 3184
Significant         
(p ≤ 0.05) 13± 2
Not Significant    
(p ≥ 0.05)
K417R 417 ± 5
Significant         
(p ≤ 0.05) 4877 ± 1188
Significant         
(p ≤ 0.05) 12 ± 3
Not Significant    
(p ≥ 0.05)
W339A 157± 11
Significant         
(p ≤ 0.05) 2546 ± 555
Significant         
(p ≤ 0.05) 16 ± 3
Significant          
(p ≤ 0.05)
Overexpression of RHA increases HTLV-1 promoter activity
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Table 3.  
Commonly found mutations in specific domains of RHA in the selected five cancers and AML with their 
mutation assessor scores (netural, low, medium or high). This data is based off 9E and color coded 
according to 9D. The percentage of total RHA alterations from Table 2 is also shown. 
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